Crinetics Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- R. Scott Struthers
- Full Time Employees
- 594
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6055 Lusk Boulevard San Diego CA United States of America 92121
- IPO Date
- Jul 18, 2018
- CIK
- 0001658247
- Website
- crinetics.com
- Similar Companies
- Business
- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) develops novel oral small-molecule therapeutics for rare endocrine diseases and endocrine-related tumors; its approved lead product PALSONIFY (paltusotine), a once-daily selective somatostatin receptor type 2 (SST2) nonpeptide agonist, treats adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option, while also advancing in Phase 3 for carcinoid syndrome associated with neuroendocrine tumors (NETs); late-stage pipeline includes atumelnant (CRN04894), an oral melanocortin type 2 receptor (MC2R) antagonist in Phase 2/3 for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome; CRN09682, a first-in-class nonpeptide drug conjugate (NDC) delivering monomethyl auristatin E (MMAE) to SST2-expressing tumors including NETs and other solid tumors, with Phase 1/2 dosing initiated in December 2025; early-stage candidates in IND-enabling studies comprise a TSH antagonist for Graves’ hyperthyroidism and orbitopathy (thyroid eye disease), SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD), and PTH antagonist for hyperparathyroidism. Founded in 2008 by Scott Struthers and colleagues with endocrinology expertise from Neurocrine Biosciences, the company is headquartered in San Diego, California, with an additional office in Zug, Switzerland, and operates globally with a focus on GPCR-targeted therapies discovered in-house. Recent developments include FDA approval of paltusotine in 2025 with commercialization underway, first patient dosing in the CRN09682 Phase 1/2 trial in December 2025 marking a milestone for its NDC platform, first patient randomization in the pivotal Phase 3 CAREFNDR trial for paltusotine in carcinoid syndrome, a $350 million oversubscribed private placement in early 2024 to fund R&D and operations, and a partnership with Sanwa Kagaku Kenkyusho for paltusotine commercialization in Japan.
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—ESI, CRNX, SOLS, and PATK
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—ESI, CRNX, SOLS, and PATK
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Why This Pharmaceutical Stock Jumped Close to 100% This Week
Why Crinetics Stock Soared 99% This Week
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Vertex's Crinetics Deal Balances Growth with Integration Risk
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
Crinetics shares surge after Vertex agrees to $10B cash buyout